Quantel Medical today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on March 25, 2019 for the New A/B/S Ultrasound Platform: ABSolu®.
“ABSolu® is our new ultrasound platform replacing our flagship ultrasound system Aviso. It is the achievement of years of work carried out by our R&D Department in collaboration with ultrasound specialists and we can say that once again, we are setting new standards in ophthalmic ultrasound imaging” said Jean-Marc Gendre, CEO of Quantel Medical. “For ophthalmologists looking for excellence in ultrasound imaging, ABSolu® is the ideal partner in their everyday practice.”
Technological breakthroughs in the ABSolu® include:
A new 5 ring annular technology 20MHz B probe that increases the depth of field by 70% thus offering in a single scan high definition information of the vitreous, retinal wall and orbit.
ABSolu® also features standardized A Mode that complies with all the hardware and software requirements necessary for proper tissue characterization essential for tumor diagnosis as per the requirements of Prof. K. Ossoinig.
Motion sensors have been integrated in all B Mode and UBM probes allowing for an automatic and constant detection of the probe position and ultrasound beam direction (patented technology).
A new signal processing for the linear 50 MHz UBM to offer high image quality of the anterior chamber and lens.
A new full HD screen compliant with section 14 of the DICOM standard, a world premiere in ophthalmic ultrasound.